Claims for Patent: 10,912,765

Summary for Patent: 10,912,765

Title:	Compositions and methods for non-surgical treatment of ptosis
Abstract:	Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Inventor(s):	Silverberg; Mark (Santa Barbara, CA)
Assignee:	VOOM, LLC (Santa Barbara, CA)
Application Number:	16/577,262
Patent Claims:	1. A method for increasing the vertical separation of the upper and lower lids of an eye of a subject in need thereof, the method comprising: administering an effective amount of oxymetazoline to the exterior surface of an eye of a subject, wherein the oxymetazoline is formulated as a pharmaceutical composition comprising about 0.1 weight percent oxymetazoline in an ophthalmologically acceptable carrier, and wherein the subject does not have an allergic ocular condition calling for treatment of the eye with oxymetazoline, the subject does not have eyelid swelling, and the subject has not undergone refractive eye surgery. 2. The method of claim 1, wherein the administering results in at least a 5% increase in the vertical separation of the upper and lower lids of the eye. 3. The method of claim 2, wherein the administering results in at least a 10% increase in the vertical separation of the upper and lower lids of the eye. 4. The method of claim 1, wherein the administering results in at least a 0.5 mm increase in the vertical separation of the upper and lower lids of the eye. 5. The method of claim 1, wherein the administering results in at least a 1 mm increase in the vertical separation of the upper and lower lids of the eye. 6. The method of claim 1, wherein the oxymetazoline is provided as a pharmaceutically acceptable salt of oxymetazoline. 7. The method of claim 1, wherein the oxymetazoline is administered as a single drop. 8. The method of claim 1, wherein the oxymetazoline is administered either once daily or at least once a day. 9. A method for increasing the vertical separation of the upper and lower lids of an eye of a subject in need thereof, the method comprising: administering to the exterior surface of an eye of a subject an effective amount of a composition comprising about 0.1 weight percent oxymetazoline in an ophthalmologically acceptable carrier, wherein the subject does not have an allergic ocular condition calling for treatment of the eye with oxymetazoline, the subject does not have eyelid swelling, and the subject has not undergone refractive eye surgery.